CN116157387B - 异喹啉化合物及其在治疗AhR失衡中的用途 - Google Patents

异喹啉化合物及其在治疗AhR失衡中的用途

Info

Publication number
CN116157387B
CN116157387B CN202180060054.5A CN202180060054A CN116157387B CN 116157387 B CN116157387 B CN 116157387B CN 202180060054 A CN202180060054 A CN 202180060054A CN 116157387 B CN116157387 B CN 116157387B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
optionally substituted
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180060054.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN116157387A (zh
Inventor
戴维·H·德鲁里
查纳·K·杰亚威克里姆
卡若林·瑟伦斯奇
苏珊·H·史密斯
瑞安·保罗·特朗普
卡罗·威尔士
替莫瑟·威尔逊
张存宇
威廉姆·祖尔彻
艾力逊·艾克斯特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Demawan Science Co ltd
Original Assignee
Demawan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demawan Science Co ltd filed Critical Demawan Science Co ltd
Publication of CN116157387A publication Critical patent/CN116157387A/zh
Application granted granted Critical
Publication of CN116157387B publication Critical patent/CN116157387B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
CN202180060054.5A 2020-07-16 2021-05-27 异喹啉化合物及其在治疗AhR失衡中的用途 Active CN116157387B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (2)

Publication Number Publication Date
CN116157387A CN116157387A (zh) 2023-05-23
CN116157387B true CN116157387B (zh) 2026-06-09

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060054.5A Active CN116157387B (zh) 2020-07-16 2021-05-27 异喹啉化合物及其在治疗AhR失衡中的用途

Country Status (10)

Country Link
US (5) US11267788B2 (enExample)
EP (2) EP4786453A2 (enExample)
JP (1) JP7867482B2 (enExample)
KR (1) KR20230041021A (enExample)
CN (1) CN116157387B (enExample)
AU (1) AU2021308209A1 (enExample)
CA (1) CA3185793A1 (enExample)
IL (1) IL299756A (enExample)
MX (1) MX2023000263A (enExample)
WO (1) WO2022015423A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置
WO2026096218A1 (en) * 2024-10-18 2026-05-07 Dermavant Sciences GmbH Pharmaceutical compositions for respiratory administration and methods of treating inflammatory diseases of the lungs
WO2026085237A1 (en) * 2024-10-18 2026-04-23 Dermavant Sciences GmbH Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
WO2018178001A1 (de) * 2017-03-29 2018-10-04 Merck Patent Gmbh Metallkomplexe
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799A (zh) * 2023-03-08 2023-10-27 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー，インコーポレイティド レトロウィルス複製の阻害のための方法
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111699192B (zh) 2018-02-13 2024-03-08 Udc爱尔兰有限公司 金属络合物
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 金屬錯合物
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
WO2018178001A1 (de) * 2017-03-29 2018-10-04 Merck Patent Gmbh Metallkomplexe
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799A (zh) * 2023-03-08 2023-10-27 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Alexia N. Kim等.Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1,3-Disubstituted Isoquinolines.ACS Catal..2020,第10卷SI第1-302页，尤其是第12、23页. *
Daulat Bikram Khadka等.Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.European Journal of Medicinal Chemistry..2017,第143卷第200-215页，尤其是第203页. *
Harnessing the reactivity of ortho-formyl-arylketones: base-promoted regiospecific synthesis of functionalized isoquinolines;Pawan K. Mishra等;Chem.Commun.;20190721;第55卷(第57期);第8278-8281页，尤其是第8279页 *
One Substrate, Two Modes of C−H Functionalization: A Metal-Controlled Site-Selectivity Switch in C−H Arylation Reactions;Virendra Kumar Tiwari等;Org.Lett.;20170106;第19卷(第1期);第262-265页，尤其是第263页 *
Reaction of Benzocyclobutenoxldes with Nitriles: Synthesis of Hypecumine and Other 3-Substituted lsoquinolines;John J. Fitzgerald等;Tetrahedron Letters;19941014;第35卷(第49期);第9191-9194页，尤其是第9192页 *
Synthesis of Substituted Isoquinolines by Electrophilic Cyclization of Iminoalkynes;Qinhua Huang等;J. Org. Chem.;20020424;第67卷;第3437-3444页，尤其是第第3440-3441页 *
Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents;Suhui Yang等;Bioorganic & Medicinal Chemistry Letters;20100703;第20卷;第5277–5281页，尤其是第5279页 *

Also Published As

Publication number Publication date
WO2022015423A1 (en) 2022-01-20
US20230124135A1 (en) 2023-04-20
US11267788B2 (en) 2022-03-08
JP7867482B2 (ja) 2026-05-29
EP4185566A4 (en) 2024-12-04
EP4185566A1 (en) 2023-05-31
US20240208910A1 (en) 2024-06-27
EP4786453A2 (en) 2026-08-05
IL299756A (en) 2023-03-01
US20250282730A1 (en) 2025-09-11
US20220153703A1 (en) 2022-05-19
AU2021308209A8 (en) 2023-04-13
US11827605B2 (en) 2023-11-28
US12252471B2 (en) 2025-03-18
US20220017468A1 (en) 2022-01-20
CN116157387A (zh) 2023-05-23
US11548853B2 (en) 2023-01-10
EP4185566B1 (en) 2026-06-24
CA3185793A1 (en) 2022-01-20
MX2023000263A (es) 2023-03-29
JP2023533855A (ja) 2023-08-04
AU2021308209A1 (en) 2023-02-09
KR20230041021A (ko) 2023-03-23

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant